Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.67 USD | +2.30% | -3.10% | -32.64% |
09/05 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
09/05 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.64% | 94Cr | |
+29.03% | 4.92TCr | |
-0.10% | 4.21TCr | |
+47.07% | 4.04TCr | |
-5.26% | 2.89TCr | |
+11.48% | 2.61TCr | |
-22.74% | 1.87TCr | |
+9.06% | 1.33TCr | |
+30.01% | 1.23TCr | |
-1.51% | 1.2TCr |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Oppenheimer Adjusts Viridian Therapeutics Price Target to $40 From $45, Maintains Outperform Rating